Kornimate/medical-research-clean huggingface dataset:
comparisons of gait analyses performance between the gaitrite walkways

Conditions: Gait Apraxia; Alzheimer Disease; Impaired Cognition

Summary: the gaitrite® system is an instrumented with resistive pressure sensors gait analyzer. it was first validate in 2001 against paper-and-pencil (intraclass correlation coefficient \[icc\] \> 95%) for spatial measures and against video-based (icc \> 93%) for temporal measures, and was thus a reliable tools to measure step lengths and times in both walkway center and left-of-center measurements. it was considered as one of the gold standards in gait analyses. this gait analyze system may distinguish prospectively faller and non-faller older adults, but it can detect spatial, temporal, and spatiotemporal measures of gait and greater variability of gait parameters which were associated with and predictive of both global- and domain-specific cognitive decline. moreover, spatiotemporal gait parameters analyzed using gaitrite® were more disturbed in the advanced stages of dementia, and more affected in the non-ad dementia than in ad suggesting that quantitative gait parameters could be used as a surrogate marker for improving the diagnosis of dementia. nevertheless, gaitrite® is not a unique system and it comprises different walkways. one of these technologies was a roll-up system (platinum plus classic, re, basic and safari), and the other was a system composed by a changeable association of plates (cirface). in order to ensure a good comparability between studies using these different walkways, it appears important to compare the performances of these walkways in gait analysis. thus, the main aim of this study was to compare the performances in gait analyze between the gaitrite® platinum plus classic and the gaitrite® cirface among older adults. secondary aims were to compare these parameters among patients with cognitive complaint, minor or major neurocognitive disorder (ncd) related to alzheimer disease.


Eligibility criteria:
inclusion criteria: * age ≥ 75 years * gait analysis performed with the two walkways superimposed during a consultation or day hospitalization exclusion criteria: * opposition to the use of the information collected for research purposes
a study of alendronate sodium vitamin d3 tablets on knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the purpose of this study is to evaluate the effect of alendronate sodium vitamin d3 tablets compared with placebo on the improvement of joint structure and joint pain in participants with knee osteoarthritis. the treatment period of this study is one year and followed-up period is 2 years. the results of knee joint mri will be evaluated by using the worms score.

this is a multi-center, randomized, double-blind, placebo-controlled study this study is planned to commence after obtaining ethics committee approval. participants will be randomised to a one-year course of alendronate sodium vitamin d3 tablets or placebo. 1:1 double blinded randomisation will be undertaken. this study plans to enroll 60 participants and will be carried out in three domestic centers (peking union medical college hospital, zhongshan hospital and the third affiliated hospital of southern medical university) with a follow-up period of 2 years. as the main goal of this exploratory study is to evaluate the effect of alendronate sodium vitamin d3 tablets compared with placebo on the improvement of joint structure and joint pain in participants with knee osteoarthritis. the primary outcome measure is worms score of knee joint mri at 6 months and 12 months.

Eligibility criteria:
inclusion criteria: 1. patients with significant knee pain (pain score≥40mm on the 100mmvas scale); 2. male or female patients, between 50-75 years old; 3. mri suggests bone marrow edema-like lesions; 4. knee osteoarthritis (in accordance with the diagnostic criteria of american college of rheumatology (acr) and chinese orthopaedic association); 5. kellgren-lawrence gradingⅰorⅱin x-ray; exclusion criteria: 1. other forms of active arthritis (such as rheumatoid arthritis or other inflammatory arthritis); 2. taken non-steroidal anti-inflammatory drugs and central analgesics (such as opioids) within two weeks； 3. liver function alt or ast is 1.5 times the upper limit of normal； creatinine clearance \<35ml/min； 4. pregnancy or suckling; 5. serious heart disease, endocrine, digestive, mental, nervous system diseases or cancer; 6. active ulcers and a history of upper gastrointestinal bleeding; 7. esophageal motility disorders, such as esophageal tardiness or stenosis; 8. renal dysfunction or osteomalacia; 9. tobacco addiction (mean 10 cigarettes per day or more) or/and alcohol addiction (mean 50ml per day or more); 10. fresh fracture in the last six months; 11. serious illnesses and life expectancy\<2 years; 12. allergic to study drugs; 13. used any study drug or device within 30 days before randomization or within the drug half-life (whichever is longer); 14. failure to take medication as required; 15. replacement surgery in the near future; 16. contraindications to mri scans (e.g. implanted pacemakers, metal sutures, shrapnel or iron filings in the eyes, claustrophobia, knees too large to use coils); 17. sensitive to or unsuitable for x-ray exposure (e.g. aplastic anemia, etc); 18. poor dental health or dental surgery in the near future.
effectiveness of ivermectin as add-on therapy in covid-19 management

Conditions: COVID 19

Summary: comparing the effectiveness of ivermectin( ivm) +hydroxychloroquin + azithromycin (azt) group to hydroxychloroquin (hcq) + azithromycin (azt)

comparing effectiveness of single dose 0.2mg/kg ivermectin (ivm) plus hydroxychloroquine (hcq) 400mg bid in first day then 200mg bid for 5 days plus azithromycin (azt) 500mg in first day then 250mg for 5 days. the comparison group was a historical control population and data collected from the current study were compared to that historical control population

Eligibility criteria:
inclusion criteria: -1. patients with age above 18 years and any gender with definite dx of covid19 and pneumonia in the ward according to the clinical, laboratory, and imaging criteria. 2. understands and agrees to comply with planned study procedures. exclusion criteria: 1. patients with hypersensitivity or severe adverse effects to ivermectin 2. renal impairment 3. hepatic impairment. 4. pregnancy or a desire to become pregnant (drug considered pregnancy category c) 5. breast feeding. 6. patient with covid 19 positive and mild no pneumonia 7. children under the age of five or those who weigh less than 15 kilograms
the correlation between oxidative stress and indinated contrast-media nephrotoxicity

Conditions: Kidney Diseases

Summary: clinically, iodinated contrast-medium (cm) is widely used in angiography and computerized tomography. cm-induced nephropathy (cmin) is one major complication after application of cm. therefore, how to prevent cmin is always one of the hot topics concerned by nephrologists, cardiologists, and radiologists. the present study is aimed to determine the norepinephrine concentration, oxidative markers, and tubular damage markers in the urine samples of patients undergoing intravenous pyelography (ivp). the working hypothesis is high-osmolarity contrast media (hocm) causes more oxidative stress and greater tubular damage than iso-osmolarity contrast media (iocm).


Eligibility criteria:
inclusion criteria: 1. adult patients (\> 18 years old) 2. undergoing ivp with an appropriate medical indication 3. signing informed consent exclusion criteria: 1. without signing informed consent

Keywords: oxidative stress markers in urine urine norepinephrine renal tubular enzyme markers
remote brain microhaemorrhages may predict haematoma in glioma patients treated with radiation therapy

Conditions: Glioma

Summary: the study aim to evaluate the prevalence of cerebral remote microhaemorrhages (rmh) and remote haematomas (rh) using magnetic resonance susceptibility-weighted imaging (swi) among patients treated for gliomas during follow-up.


Eligibility criteria:
inclusion criteria: * glioma exclusion criteria: -
dexamethasone-implant for the treatment of macula edema due to irvine gass syndrome

Conditions: Macular Edema; Visual Acuity

Summary: to analyze macula edema formation after cataract surgery called irvine-gass-syndrome.

20 to 25 patients suffering from irvine gass syndrom should be monitored for at least six months, controlled monthly. in all cases best corrected visual acuity, spectralis-oct (volume thickness scan), fundus photography (optomap), intraocular pressure, slitlamp assessment and indirect ophthalmoscopy should be performed on every visit. fluorescein angiography should be performed at baseline and after 3 and 6 months. inclusion criteria: patients older than 18 years who develop macula edema secondary to cataract surgery. - consent agreement - patients should be informed that it is possible to get an active medication (ozurdex implant) as an "on label" indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of "uveitis posterior". exclusion criteria: visual acuity worse than 20/400, known history of glaucoma and steroid response, any macular disease interfering with visual acuity (dme, amd, etc.), history of vitrectomy, use of systemic, periocular, or intraocular corticosteroids within 30 days. outcome: * bcva * patients suffering from diabetes mellitus should be evaluated also separately. * change in central retinal thickness using optical coherence tomography (oct) * secondary parameters (elevated iop, retinal detachments, vitreous hemorrhage, endophthalmitis rates)

Eligibility criteria:
inclusion criteria: patients older than 18 years who develop macula edema secondary to cataract surgery exclusion criteria: visual acuity worse than 20/400, known history of glaucoma and steroid response, any macular disease interfering with visual acuity (dme, amd, etc.), history of vitrectomy, use of systemic, periocular, or intraocular corticosteroids within 30 days.

Keywords: macular edema, irvine gass syndrome, ozurdex
growth hormone's effect on endothelial progenitor cells

Conditions: Cardiovascular Disease

Summary: to assess the effect of short-term low-dose growth hormone therapy on the mobilization of endothelial progenitor cells from the bone marrow within a group of healthy adults.

we are proposing a pilot study to assess the effect of the administration of recombinant human growth hormone on the number of endothelial progenitor cells (epc's) in the peripheral circulation. an increase in the number of epc's is viewed as beneficial, as it has been postulated that they provide an endogenous repair mechanism to counteract endothelial injury. additionally, a reduced number of epc's has been found to independently predict atherosclerotic disease progression. mechanisms proposed for enhancing the number of circulating epc's and their function include an increase in proliferation, mobilization from the bone marrow, or prevention of epc apoptosis. thus, a pharmacologic manipulation of the number of epc's in the peripheral circulation could potentially serve as a mechanism by which endothelial function, and thus vascular health, may be improved.

Eligibility criteria:
inclusion criteria: * adults age 18 thru 65 * serum igf-1 in the lower half of the age and gender-specific normal range at the time of screening visit exclusion criteria: * systemic hypertension, as defined as current bp \>140/90 on screening visit, or taking anti-hypertensive therapy. * diabetes mellitus, as defined by known diagnosis or fasting blood glucose \>126 at the time of screening visit. * women who are pregnant or nursing, as confirmed by history or seum beta-hcg at the time of screening visit. * women who are taking exogenous oral estrogens of any kind. * personal history of active cancer or recurrence within the past 10 years, with the exception of non-melanoma skin cancer. * personal history of an untreated benign intracranial neoplasm. * initiation of statin therapy during the course of the study. * a serum igf-1 level below the age and gender-specific normal range at the time of screening visit. * renal insufficiency, as defined by a gfr \<60 mls/min/1.73 m2 upon renal function panel at the time of screening visit. * hepatic insufficiency, as defined by an ast and/or alt \>twice the upper limit of normal at the time of screening visit.

Keywords: growth hormone cardiovascular system endothelial progenitor cells
sokary mobile application with type ii diabetes

Conditions: Type II Diabetes

Summary: android mobile application named (sokary)

android mobile application named (sokary) which means diabetes was selected as an example of mobile health application as it has the advantage of arabic interface, free use it allows users to record his/their blood glucose level, nutrition and physical activity, then provide the user with statistics for those readings. the application also sends notifications to the users such as medication reminders and healthy lifestyle advice.

Eligibility criteria:
inclusion criteria: * be familiar with the use of mobile health applications. * own a smartphone with an android operating system. * able to use the internet either through wi-fi network and\\or mobile data. exclusion criteria: -

Keywords: mobile phone application dm type ii egypt compliance
efficacy of symbicort pmdi administered once daily in adolescents and adults during 12 weeks - stem

Conditions: Asthma

Summary: the purpose of this study is to compare a dose of symbicort taken once daily with other dosage regimens of symbicort , budesonide and placebo for the treatment of asthma in adolescents and adults


Eligibility criteria:
inclusion criteria: * diagnosis of asthma and baseline lung function tests as determined by the protocol * required and received treatment with inhaled corticosteroids within the timeframe and doses specified in the protocol exclusion criteria: * severe asthma * has required treatment with any non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in protocol or requires treatment with beta-blockers

Keywords: asthma adolescents adults symbicort budesonide/formoterol budesonide
imaging study of glioblastomas treated with avastin

Conditions: Malignant Gliomas

Summary: this study aims to assess the effect of avastin on brain vascularity and blood-brain permeability using dynamic contrast ct scans (dect) and mri imaging. previous publications have documented the method by which dect can determine alterations in vascular volume and tissue permeability within tumors and normal brain tissue. functional maps of cerebral blood flow cerebral blood volume and permeability-surface area can be generated from the dect studies to assess tumor perfusion. mri spectroscopy analyzes brain chemistry to detect tumour versus edema versus normal brain. thirty patients will receive mri spectroscopy and dect imaging at the time of presumed recurrence and 3 months later. 15 patients who do not receive avastin and 15 patients who do receive avastin as standard treatment for recurrence will be studied with dect and mri spectroscopy at baseline and then again in 3 months.

the clinical determination of the point of tumour progression or response is difficult to determine using standard diagnostic imaging ie ct/mri especially following previous treatment with surgery, radiation and chemotherapy. hemorrhage, edema, inflammation and vascular necrosis. both mr spectroscopy and dect have been reported as being able to define areas of recurrent tumour as opposed to treatment-related effects. we wish to investigate the correlation between mr spectroscopy and dect in assessing tumour progression or response to avastin in comparison with patients not receiving avastin. health canada has approved avastin for clinical use in patients with recurrent glioblastoma who have previously received temozolomide and radiotherapy. we propose to perform a dect scan at baseline at presumed tumour progression and again 3 months to determine the effects of tumour progression/response on blood brain barrier permeability and vascular volume. the group of 15 patients will be compared to a group of 15 patients who do not receive avastin at recurrence involving dect scanning and mr spectroscopy at the time of the radiological progression and 3 months later.

Eligibility criteria:
inclusion criteria: * histological diagnosis of glioblastoma with clinical or radiological evidence of progression as indicated by the rano criteria 19 * previous radiation and temozolomide chemotherapy * patients must be receiving avastin chemotherapy as second-line treatment if in the avastin group * study-specific consent exclusion criteria: * failure to meet inclusion criteria * pregnant or lactating patients * allergy to iodine or ct contrast precludes dect component of study * claustrophobia precludes mr spectroscopy component of study * internal metal which would preclude an mri scan

Keywords: dynamic enhanced ct scan mri spectroscopy recurrent gliomas
biomarkers to predict gain from therapy in motor stroke

Conditions: Stroke; Motor Activity; Biomarker

Summary: the aim is to determine predictors of treatment response, i.e gain from rehabilitation training, in post stroke upper limb deficits. the investigators will like to answer the following question: "what is this patient's potential for recovery, given his profile?" the investigators propose to conduct a longitudinal physiopathological study on the stroke patients with motor deficits who entered the rehab center of pitié salpêtrière hospital. the investigators will benefit from the organization, which is already in place (clinical asssessments and training) to add mri, tms and eeg recordings, as well as genotype analysis before the training offered in the rehabilitation unit. the investigators will repeat these assessments after the training (immeadiately and 6 weeks after).

the protocol is based on 10 visits. the three main one are v1, v9 and v10. v1, v9 and v10 are the assessments visits with clinical scores, mri tms and eeg recordings. these are made before the training (v1), immediately after the 6 weeks of training (v9) and 6 weeks after (v10) v5 is a visit where the investigators will clinically assess the patients at three weeks of the training. the other visits (v2, v3, v4, v6, v7, v8) consist in recording an eeg while patients are under training each week during six weeks.

Eligibility criteria:
inclusion criteria: (i) first-ever stroke patients (ii) upper limb motor impairment (fugl meyer scale) (iii) post stroke delay between 7 and 42 days (iv) affiliated to french health care (v) suitable for task based oriented training in the rehab center exclusion criteria: (i) age \ 85 years (ii) hemianopia (iii) contra-indications to mri or tms assessments (iv) life threatening conditions (v) patients under legal protection (vi) pregnancy
effect of various virtual reality exercise individuals with low back pain

Conditions: Low Back Pain

Summary: posture is defined as the best position formed by the segments that make up the body in a harmonious arrangement with each other. muscle strength, which is one of the primary factors in providing a static or dynamic posture, is achieved thanks to the antigravity muscles that keep the body upright against gravity. proper posture is ensured by a good body balance.

advances in technology can influence healthcare providers to create alternative and new treatment options. sg/lv applications have also gained momentum in the field of rehabilitation. studies have shown that 12-week programs, especially in diseases affecting the balance and vestibular system, can achieve more effective results than standard physiotherapy programs in both upper and lower extremity functions, balance, walking parameters, fall risk and cognitive parameters. the use of popular video game-based exercises, such as xbox, or "exergaming," has evolved to become therapeutic tools for rehabilitation. accessible as technology evolves into more and more, equipment like biodex could be an alternative way to assess and train balance

Eligibility criteria:
inclusion criteria: * 18-60 with nonspecific chronic low back pain exclusion criteria from the study: * cognitive impairment * disc herniation * neurological deficit * respiratory problems
virtual reality in motor performance and quality of life in patients with parkinson's disease

Conditions: Parkinson Disease

Summary: treatment with nintendo wii is higher to physical therapy conventional in the quality of life and motor performance in patients with parkinson's disease.

the aim of this study is to assess if the treatment of rehabilitation with nintendo wii is higher to the conventional in the quality of life and motor performance in patients with parkinson's disease.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of parkinson's disease * both the sex with age between 50 and 80 years * to be in it i serve as apprentice of 1 the 3,0 in the scale of hoehn yahr exclusion criteria: * cognitive impairment * poorly controlled arterial hypertension * poorly controlled cardiopathy

Keywords: parkinson's disease physical therapy virtual reality quality of life motor performance
bilateral tap and rs blocks using liposomal bupivacaine/bupivacaine vs. regular bupivacaine in laparoscopic colectomy

Conditions: Bowel Disease

Summary: this study will be a single center, prospective triple blinded randomized controlled study, comparing the use of liposomal bupivacaine (exparel) to regular bupivacaine with adjuncts in bilateral mid-abdominal transverse abdominis plane (tap) blocks for patients undergoing laparoscopic colectomy procedures.


Eligibility criteria:
inclusion criteria: * patients scheduled for elective laparoscopic colectomy surgery to be performed by one of the 4 colorectal surgeons in the study. * english speaking patients * patients with american society of anesthesiology (asa) physical status score i- iv exclusion criteria: 1. emergency laparoscopic colectomy surgery 2. patients with distant metastatic cancers (e.g. bone, lung, brain). 3. scheduled for multi organs resection surgery in addition to colectomy. 4. patients with contraindications to tap or rs blocks including but not limited to anatomical abnormality, previous surgical intervention that limits or prevents receiving bilateral tap blocks (e.g. surgical mesh at the site of tap or rs block), or infection at the injection site. 5. current colostomies. 6. history of allergy to local anesthetics. 7. coagulopathy or coagulation disorder. also patients who are receiving antithrombotic medications as a contraindication to receiving single shot peripheral nerve blockade as per the most recent american society of regional anesthesiology (asra) guidelines.16 8. weight \< 40 kg, as 40 ml of bupivacaine 0.25%, or combination of 20 ml of bupivacaine 0.25% with 20 ml of liposomal bupivacaine is greater than the maximal dose allowed, given concern for local anesthetic toxicity. 9. patients who take long acting opioid medication, or on continuous opioid \> 50 mme per day for at least 30 days within 90 days prior to surgery. also patients who have chronic pain syndrome with a recent preoperative consultation to the chronic pain service. 10. patients with current substance abuse, or history of substance abuse within 3 months, this includes any illicit drugs or excessive alcohol consumption as defined 4 or more drinks per day or 8 or more drinks per week for women and 5 or more drinks per day or 15 or more drinks per week for men.15 11. pregnant, nursing, or planning to become pregnant during the study or within 1 month postoperatively 12. refusal or lack of providing the study consent

Keywords: liposomal bupivacaine exparel bupivacaine laparoscopic colectomy transverse abdominis plane blocks (tap) regional anesthesia rectus sheath block